Log in here
Top Journalists
>
Robert Stott

Robert Stott

Editorial Director at Healio

Contact this person
Email address
r*****@*******.comGet email address
Influence score
54
Phone
(XXX) XXX-XXXXGet mobile number
Location
United States
Languages
  • English
Covering topics
  • Health & Medicine

View more media outlets and journalists by signing up to AI PR

View latest data and reach out all from one place
Sign up to AI PR Toolkit

Recent Articles

healio.com

‘Vicious cycle’: Creeping fat first protects, then drives fibrosis in Crohn’s disease

LAS VEGAS — What if creeping fat in Crohn’s disease isn’t collateral damage, but rather the body’s attempt to trap microbiota escaping the intestine, only to become a driver of fibrosis and disease progression itself?Data presented by Suzanne Devkota, PhD, during Crohn’s & Colitis Congress suggest that when intestinal microbiota fugitives persist in the adipose
9 months ago
healio.com

Set boundaries, expectations to keep ‘mentorship malpractice’ from ...

LAS VEGAS — Effective mentorship can accelerate careers, but toxic mentoring behaviors can just as easily derail academic progress if left unchecked, Frank I. Scott, MD, MSCE, warned attendees at Crohn’s & Colitis Congress.“We know that mentorship can positively influence career trajectories,” Scott, codirector of Crohn’s & Colitis Foundation’s IBD
9 months ago
healio.com

‘No antifibrotics, no endpoints’: Breaking therapeutic catch-22 in ...

LAS VEGAS — Therapeutic progress for fibrostenotic Crohn’s disease has been stalled in a paradox: Antifibrotic drugs require endpoints for development, yet meaningful endpoints cannot be established without effective antifibrotic therapies.
9 months ago
healio.com

‘Major shifts’ in AGA guidance for IBD prioritize Mediterranean, wh...

LAS VEGAS — AGA clinical practice guidelines for inflammatory bowel disease management have undergone “major shifts” in recent years, placing diet front and center and urging patients to adhere to Mediterranean or whole-food diets. “We know that diet impacts the GI tract significantly, and it impacts the areas that we feel are the idiopathogenesis of IBD,” David Suskind, MD, professor of
10 months ago
healio.com

Resmetirom upholds liver stiffness, biomarker gains in MASH cirrhos...

Resmetirom sustained improvements in liver stiffness and several liver biomarkers among patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis at 2 years, according to data presented at The Liver Meeting.
12 months ago
healio.com

Tulisokibart linked to ‘deep, durable remission’ in ulcerative coli...

PHOENIX — Tulisokibart was linked to clinical, endoscopic and histologic remission in patients with ulcerative colitis following 12 weeks of induction therapy and 38 weeks of maintenance among responders, according to data presented here.The researchers also reported a strong association between clinical remission achieved with tulisokibart (MK-7240, Merck) at weeks 12 and 50 and
12 months ago
healio.com

MMF rivals azathioprine with fewer cytopenias, comparable safety in...

PHOENIX — Mycophenolate mofetil outperformed azathioprine as maintenance therapy for patients with autoimmune hepatitis, especially those with hematologic risks, according to data presented at ACG Annual Scientific Meeting.
about 1 year ago
healio.com

VIDEO: Virtual clinic offers ‘safety net’ for patients with cancer ...

A virtual multispecialty cancer support clinic intends to “connect the dots” to match patients with specialists within 3 days to help manage side effects of cancer treatment, including drug reactions and treatment-emergent adverse events.“About 85% of cancer patients receive their cancer treatments in community cancer centers where access to specialists like endocrinologists,
about 1 year ago
healio.com

FDA rejects Genentech’s glofitamab-gxbm for DLBCL, stymied by insuf...

The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license application seeking approval for glofitamab-gxbm as a treatment for relapsed or refractory diffuse large B-cell lymphoma.In its letter, the agency cited that data from the phase 3 STARGLO study failed to provide sufficient evidence to support glofitamab-gxbm (Columvi) as
over 1 year ago
healio.com

MITIGATE: Uplizna ‘even better’ for IgG4-related disease with GI in...

SAN DIEGO — Inebilizumab was especially effective for patients with pancreatic and biliary immunoglobulin G4-related disease, with significantly reduced glucocorticoid use for disease control, according to analysis of the MITIGATE trial.Although data from The New England Journal of Medicine published in November 2024 confirmed that inebilizumab (Uplizna, Amgen) significantly reduced the
over 1 year ago
healio.com

Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.Previously approved for ulcerative colitis in September 2024, Tremfya (guselkumab) is now the third IL-23p19 specific inhibitor approved for
over 1 year ago